VJOncology Podcast

Episódios

• 
  Updates in skin cancer from ASCO 2026 07.08.2026 16min

  In this week’s VJOncology podcast, we explore the latest advances in skin cancer from ASCO 2025, with a focus on melanoma and emerging cellular therapies. Join Alexandra Haugh of Massachusetts General Hospital Cancer Center, Boston, MA, Kalijn Bol of Radboud University Medical Center, Nijmegen, Netherlands, Allison Betof Warner of Stanford University, Stanford, CA, Omid Hamid of The Angeles Clinic and Research Institute, Los Angeles, CA, and Peter Forsyth of Moffitt Cancer Center, Tampa, FL, as they discuss real-world outcomes with lifileucel, treatment sequencing in BRAF-mutated melanoma, emerging cellular therapies and vaccines, and preclinical approaches to CAR T-cell therapy for leptomeningeal disease.
• 
  iwCAR-T 2026: advances in TIL therapy for solid tumors 31.07.2026 19min

  Welcome to another episode of VJOncology Podcast, featuring a roundtable discussion from iwCAR-T 2026, which took place in Tampa, FL. This week, our experts explore advances in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Join Benjamin Creelan from Moffitt Cancer Center, Rodabe Amaria from the University of Texas MD Anderson Cancer Center, Daniel Olson from the University of Chicago, and Lilit Karapetyan from Moffitt Cancer Center as they discuss sequencing, duration issues and armoring approaches for TIL therapy in melanoma and other solid tumors.
• 
  Beyond the algorithm: trust, evidence and equity in AI-enabled cancer care 23.07.2026 17min

  In this week’s VJOncology podcast, we explore the latest developments in artificial intelligence (AI) in oncology and their potential to transform cancer care. Join Eleonora Teplinsky, Valley Health System, Paramus, NJ, Gil Shamai, Technion–Israel Institute of Technology, Haifa, Israel, Matthew Kurian, St. Elizabeth Healthcare, Edgewood, KY, Jai Patel, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, and Marie Hanaoka, Institute of Science Tokyo, Japan, as they discuss AI-driven patient education, biomarker prediction, clinical decision-making, trial matching, and surgical training, alongside the opportunities and challenges of integrating artificial intelligence into oncology practice.
• 
  GU cancer highlights from ASCO 2026 17.07.2026 16min

  In this week’s VJOncology podcast, we present highlights in genitourinary cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Andrew Armstrong of Duke University Medical Center, Srikala Sridhar of the Princess Margaret Cancer Centre, Tian Zhang of UT Southwestern Medical Center, and Lucia Nappi of the University of British Columbia as they discuss key data and clinical perspectives across prostate, bladder, kidney and testicular cancer, including the PROTEUS, CHAMP, TALAPRO-3, A-DREAM and SWOG S1823 trials, as well as the role of enfortumab vedotin and pembrolizumab in bladder cancer.
• 
  Top updates from the ESMO Gastrointestinal Cancers Congress 2026 10.07.2026 18min

  In this week’s VJOncology podcast, we had the opportunity to attend the 2026 ESMO Gastrointestinal Cancers Congress in Munich, Germany, where we explored the latest advances across gastrointestinal malignancies. Join Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona, Spain, Giulia Martini, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, Lorenza Rimassa, Hunimed University, Milan, Italy, Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan, and Silvio Ken Garattini, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, as they discuss emerging KRAS G12D-targeted therapies in pancreatic cancer, ctDNA-guided treatment strategies in metastatic colorectal cancer, novel targeted approaches for biliary tract cancer, HER2-directed therapies in gastroesophageal cancer, and evolving treatment paradigms in hepatocellular carcinoma and gastric cancer.
• 
  Highlights in lung cancer from ASCO 2026: LIBRETTO-432, CROWN, and more 26.06.2026 16min

  This week, VJOncology brings you lung cancer highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Join Alessandro di Federico from the Memorial Sloan Kettering Cancer Center, Erika Ruiz-Garcia of the Instituto Nacional de Cancerologia, Nandini Menon of the Tate Memorial Centre and Bjorn Henning Gronberg of the Norwegian University of Science and Technology as they discuss key trials and data in lung cancer from the meeting. They explore results from the LIBRETTO-432, TRITON and FLAME trials, as well as 7-year follow up data from the CROWN trial. In addition, they discuss two trials of KRAS G12C inhibitors, a study examining low-dose pembrolizumab and a trial of thoracic radiotherapy.
• 
  Breast cancer highlights from ASCO 2026 19.06.2026 17min

  For this week’s VJOncology podcast, we bring you highlights in breast cancerfrom the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting inChicago, IL. Join Oleg Gluz of Evang. Krakenhaus “Bethesda” Klinik, Jana deBoniface of the Karolinska Institutet, Peter Schmid of Queen Mary University ofLondon and Erika Hamilton of the Sarah Cannon Research Institute as theydiscuss key trials and what this means for clinical practice. They explore pooledanalysis from the ADAPT and PlanB trials, results from the SENOMAC trial ofaxillary lymph node dissection omission, menopausal status data from the lidERAtrial, final analysis from KEYNOTE-522 and subgroup analyses fromHER2CLIMB-05.
• 
  Gastrointestinal cancer updates at ASCO 2026: RASolute 302, EMERALD-3, and more 12.06.2026 16min

  In this week’s VJOncology podcast, we had the opportunity to attend the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL, where we explored the latest advances in gastrointestinal (GI) cancers. Join Ghassan Abou-Alfa and Yelena Janjigian of Memorial Sloan Kettering Cancer Center, Scott Kopetz of The University of Texas MD Anderson Cancer Center, and Choong-Kun Lee of Yonsei University as they discuss emerging treatment strategies in GI cancers, including findings from the EMERALD-3, RASolute 302, DESTINY-Gastric03, BREAKWATER, and HERBOT trials, alongside the growing role of targeted therapies, HER2-directed approaches, and biomarker testing in gastrointestinal oncology.
• 
  Highlights from ASCO 2026 08.06.2026 18min

  This episode of VJOncology podcasts brings together five expert interviews from the 2026 ASCO Annual Meeting in Chicago, covering practice-changing data across prostate cancer, sarcoma, lung cancer, colorectal cancer, and triple-negative breast cancer. Highlights include final analysis results from the PROTEUS trial supporting perioperative apalutamide plus ADT as a new standard of care, SARC041 data on abemaciclib in dedifferentiated liposarcoma, lung cancer updates from the DeLLphi-304, LIBRETTO-432, and ALCHEMIST trials, BREAKWATER Cohort 3 data establishing encorafenib plus cetuximab with FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer, and PFS2 analyses from ASCENT-04 reinforcing sacituzumab govitecan plus pembrolizumab in metastatic triple-negative breast cancer.
• 
  iwCAR-T 2026: CARs targeting cell surface proteins 15.05.2026 16min

  In this roundtable discussion from iwCAR-T 2026, a panel of experts in cell therapy for solid tumours discuss the current state of CAR T-cell therapy beyond hematological malignancies. The panel explores key challenges including target selection, T-cell persistence, and the immunosuppressive tumour microenvironment, alongside emerging strategies such as armoured CARs, combination approaches with targeted therapies, and in vivo CAR T-cell generation. The discussion also addresses the importance of patient selection and earlier lines of therapy, and considers how academic–industry partnerships and evolving manufacturing technologies may shape the future of the field.
• 
  Bladder Cancer Awareness Month: subtypes, diagnostics & breakthroughs 08.05.2026 15min

  In this week’s VJOncology podcast, we mark Bladder Cancer Awareness Month by exploring recent advances in bladder cancer research and clinical care. Join Joaquim Bellmunt of Dana-Farber Cancer Institute, Boston, MA, Eva Compérat of Medical University of Vienna, Vienna, Austria, Roberto Contieri of Humanitas University, Milan, Italy, and Vadim Koshkin of University of California, San Francisco, CA, as they discuss circulating tumor DNA for MRD monitoring in muscle-invasive bladder cancer, advances in intravesical therapies and urinary tract diagnostics, de-escalated approaches for low-grade non-muscle-invasive disease, and the evolving molecular classification of bladder cancer into luminal and basal subtypes.
• 
  Oncology highlights from AACR 2026 01.05.2026 17min

  In this week’s VJOncology podcast, we bring you key updates from the 2026 AACR meeting across early-phase immuno-oncology and targeted therapy. Join leading experts Bruno Bockorny, Beth Israel Deaconess Medical Center, Boston, MA, Byoung Chul Cho, Yonsei University, Seoul, South Korea, Kristen Pauken, and Timothy Yap, MD Anderson Cancer Center, Houston, TX, as they discuss the clinical challenges of immune-related adverse events with checkpoint inhibitors, early signals from first-in-human studies of PLN-101095 in refractory solid tumors, emerging safety and activity data from a Phase I dose-escalation study of denikitug, and updated results of elisrasib monotherapy in previously treated KRAS G12C-mutant non-small cell lung cancer.
• 
  Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC 30.04.2026 17min

  In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.
• 
  Head and neck cancer awareness month: key trials and evolving treatment strategies 17.04.2026 13min

  In this week’s VJOncology podcast, we mark Head and Neck Cancer Awareness Month by exploring recent advances in head and neck cancer. Join Kevin Harrington, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, Takeshi Kodaira, Aichi Cancer Center, Nagoya, Japan, Andreas Dietz, University Hospital of Leipzig, Leipzig, Germany, and Nabil Saba, Emory University, Atlanta, GA, as they discuss key clinical trial updates, including OrigAMI-4, ASPEN-04, CompARE, and JCOG1912, alongside evolving strategies optimizing radiation dosing, reducing late toxicities, and improving management of recurrent respiratory papillomatosis.
• 
  Lung cancer highlights from the 24th BTOG annual conference 27.03.2026 18min

  In this week’s VJOncology podcast, we had the opportunity to attend the 2026 British Thoracic Oncology Group (BTOG) conference, where we explored key developments in lung cancer screening, diagnostics, and clinical research. Join Robert Rintoul, University of Cambridge, Cambridge, UK, Lauren Dixon, London School of Hygiene & Tropical Medicine, London, UK, Mariana Brandao, Jules Bordet Institute, Brussels, Belgium, and Anna Bibby, North Bristol NHS Trust, Bristol, UK as they discuss national screening updates, insights from the State of the Nation report, ongoing EORTC trials, and the clinical implications of incidental findings in lung cancer screening programs.
• 
  Immuno-oncology updates from 12th Immunotherapy of Cancer Conference 20.03.2026 12min

  In this week’s VJOncology podcast, we had the opportunity to attend the 12th Immunotherapy of Cancer (ITOC) Conference, where we explored cutting-edge developments in cancer immunotherapy and tumor biology. Join David Giles of Washington University in St. Louis, MO, Bernard Fox of Providence Cancer Institute, Portland, OR, and Krijn Dijkstra of Netherlands Cancer Institute, Amsterdam, Netherlands as they discuss innovative approaches including live cell and dark antigen vaccines, adoptive cell therapy in melanoma, and tumor-intrinsic mechanisms shaping immune exclusion in colorectal cancer.
• 
  Top updates from ASCO GU 2026: latest trials in prostate, kidney, and bladder cancer 06.03.2026 17min

  In this week’s VJOncology podcast, we will be covering highlights from ASCO GU 2026 in San Francisco, CA. Dive into the latest advancements in genitourinary cancers, including groundbreaking trial results and emerging treatment strategies. In this episode, join Enrique Gallardo, MD, Parc Taulí University Hospital, Barcelona, Spain, Jan-Jaap Mellema, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, Pooja Ghatalia, MD, Fox Chase Cancer Center, Philadelphia, PA, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and, Aly-Khan Lalani, MD, McMaster University, Hamilton, Canada, as they discuss critical findings from ASCO GU 2026, including combination therapies, innovative approaches to bladder preservation, and novel biomarkers in prostate and renal cell carcinoma.
• 
  Esophageal cancer awareness month: from multidisciplinary dialogue to clinical impact 20.02.2026 17min

  In this week’s VJOncology podcast, as part of Oesophageal Cancer Awareness Month in the UK, we are pleased to bring you the latest advances shaping the treatment landscape for oesophageal and gastroesophageal cancers. Join leading experts Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, Berend van der Wilk, MD, Erasmus MC Cancer Institute, Kohei Shitara, MD, National Cancer Center Hospital East, and Ian Chau, MD, Royal Marsden Hospital, as they discuss pivotal data from key clinical trials across the disease spectrum. Our expert panel highlights how these data are refining first-line strategies, informing organ-preserving approaches, and advancing biomarker-driven therapies in oesophageal and gastroesophageal cancers.
• 
  ctDNA-guided surveillance and treatment monitoring in breast cancer 13.02.2026 16min

  In this week’s VJOncology podcast, we are delighted to bring you the latest advances in circulating tumor DNA (ctDNA)-informed monitoring and follow-up strategies in breast cancer. Join leading experts Wolfgang Janni, MD, University of Ulm, Ulm, Germany, Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, and Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MA, as they explore cutting-edge data from key studies including SURVIVE, LEADER, a Phase I/II trial of vepdegestrant, and PACE. Together, they discuss the evolving role of circulating tumor DNA in detecting molecular relapse, guiding early intervention strategies, monitoring treatment response, and predicting resistance across early and advanced ER+/HER2-negative and HR+/HER2-negative breast cancer settings.
• 
  What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more 06.02.2026 18min

  In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.